Document is current
Any future updates will be listed below
-
Authors
Sugimoto, Akira
Kaneda, Hiroyasu
Yoshimoto, Naoki
Nagata, Kenji
Fujii, Tatsuo
Michimoto, Koichi
Ueno, Shunsuke
Kamimori, Takao
Ishii, Yoshie
Sakagami, Mai
Inokuchi, Haruo
Shibuya, Keiko
Mizutani, Megumi
Nagamine, Hiroaki
Nakahama, Kenji
Matsumoto, Yoshiya
Tani, Yoko
Sawa, Kenji
Kawaguchi, Tomoya
- License Information
-
More Information
Article History
Received: 26 March 2024
Accepted: 13 August 2024
First Online: 23 August 2024
Competing interests
: Akira Sugimoto reports a relationship with Chugai Pharmaceutical Co Ltd that includes speaking and lecture fees. Hiroyasu Kaneda reports a relationship with AstraZeneca, Chugai Pharmaceutical Co Ltd, Ono Pharmaceutical Co Ltd, and Bristol Myers Squibb Co that includes speaking and lecture fees. Naoki Yoshimoto reports a relationship with AstraZeneca, Boehringer Ingelheim Japan Inc, Bristol Myers Squibb Co, Eli Lilly and Company, Kyowa Kirin Co Ltd, MSD, Nippon Kayaku Co Ltd, Taiho Pharmaceutical Co Ltd, and Takeda Pharmaceutical Company Limited that includes speaking and lecture fees. Tatsuo Fujii reports a relationship with AstraZeneca that includes speaking and lecture fees. Shunsuke Ueno reports a relationship with MSD and Chugai Pharmaceutical Co Ltd that includes speaking and lecture fees. Takao Kamimori reports a relationship with AstraZeneca, MSD, Nippon Boehringer Ingelheim Co Ltd, Novartis Pharma, Sanofi, and Takeda Pharmaceutical Company Limited that includes speaking and lecture fees. Haruo Inokuchi reports a relationship with AstraZeneca, Elekta, Boston Scientific Corp, Daiichi Sankyo Co Ltd, and Regeneron Pharmaceuticals Inc. that includes speaking and lecture fees. Keiko Shibuya reports a relationship with AstraZeneca, Takeda Pharmaceutical Company Limited, and Elekta that includes speaking and lecture fees. Yoko Tani reports a relationship with AstraZeneca, Kyowa Kirin Co Ltd, and Chugai Pharmaceutical Co Ltd that includes speaking and lecture fees. Kenji Sawa reports a relationship with Eli Lilly Japan KK, AstraZeneca, Kyowa Kirin Co Ltd, Ono Pharmaceutical Co Ltd, Nippon Kayaku Co Ltd, Chugai Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd, and MSD that includes speaking and lecture fees. Tomoya Kawaguchi reports a relationship with Chugai Pharmaceutical Co Ltd, MSD, AstraZeneca, Taiho Pharmaceutical Co Ltd, Boehringer Ingelheim, Ono Pharmaceutical Co Ltd, Bristol Myers Squibb Co, and Pfizer Inc that includes speaking and lecture fees. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
